Cytosorbents Corporation (CTSO)

US — Healthcare Sector
Peers: OSA  LIVN  ELMD  KIDS  SRDX  NPCE  CLPT  TELA  CVRX  OFIX  AORT  HSKA  FNA  INGN  LUNG  APYX 

Automate Your Wheel Strategy on CTSO

With Tiblio's Option Bot, you can configure your own wheel strategy including CTSO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CTSO
  • Rev/Share 0.4554
  • Book/Share 0.2395
  • PB 3.5079
  • Debt/Equity 1.855
  • CurrentRatio 2.6102
  • ROIC -0.3387

 

  • MktCap 52592736.0
  • FreeCF/Share -0.2486
  • PFCF -3.4836
  • PE -3.2207
  • Debt/Assets 0.5312
  • DivYield 0
  • ROE -1.1439

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025
CTSO
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral

Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents Therapy PRINCETON, N.J. , May 22, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today's presentation at EuroPCR 2025 of a new contemporary real-world data analysis highlighting the intraoperative use of its technology to significantly reduce the severity of bleeding in urgent coronary artery bypass grafting (CABG) patients on the blood thinner, ticagrelor (Brilinta®, AstraZeneca) who had not completed …

Read More
image for news CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
CTSO
Published: April 21, 2025 by: PRNewsWire
Sentiment: Neutral

PRINCETON, N.J. , April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA).

Read More
image for news CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants
CTSO
Published: April 04, 2025 by: PRNewsWire
Sentiment: Neutral

PRINCETON, N.J. , April 4, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced the extension of the expiration date of the Series B Right Warrants (the "Series B Right Warrants") issued in the Company's Rights Offering in January 2025.

Read More
image for news CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants

About Cytosorbents Corporation (CTSO)

  • IPO Date 2006-08-08
  • Website https://www.cytosorbents.com
  • Industry Medical - Devices
  • CEO Dr. Phillip P. Chan M.D., Ph.D.
  • Employees 149
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.